digoxin + ivabradine

A combination of two heart rate-lowering medications with different mechanisms of action. Digoxin is a cardiac glycoside that inhibits the sodium-potassium ATPase pump, increasing intracellular calcium and improving cardiac contractility while slowing heart rate. Ivabradine selectively inhibits the sinus node If-channels (HCN channels), resulting in heart rate reduction without affecting cardiac contractility or blood pressure. This combination has been studied for heart failure management, particularly in patients with inadequate rate control on maximum tolerated beta-blocker therapy. Studies suggest potential benefits in both heart failure with reduced ejection fraction (HFrEF) and diastolic heart failure with preserved systolic function (HFpEF), although comparative effectiveness varies depending on the condition. A moderate drug interaction exists between digoxin and ivabradine, potentially requiring monitoring when used together. Current research, such as the BRAKE-AF study, is evaluating the combination or ivabradine alone (compared to digoxin) in specific patient populations like those with permanent atrial fibrillation refractory to other rate control agents.